



## **TRACON to Report Second Quarter 2015 Company Highlights and Financial Results on August 5, 2015**

**San Diego, CA – July 29, 2015** – TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its second quarter 2015 financial and operating results after the close of U.S. financial markets on Wednesday, August 5, 2015. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:

Date: August 5, 2015

Time: 4:30 pm Eastern Daylight Time (1:30 pm Pacific Daylight Time)

Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)

Passcode: 93406510

Via web: [www.traconpharma.com](http://www.traconpharma.com); "Events and Presentation" section within the "Investors" section

A replay of the webcast will be available for 60 days on the website.

### **About TRACON**

TRACON develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at [www.traconpharma.com](http://www.traconpharma.com).

#### Company Contact:

Casey Logan  
Chief Business Officer  
(858) 550-0780 ext. 236  
[clogan@traconpharma.com](mailto:clogan@traconpharma.com)

#### Investor Contact:

Andrew McDonald  
LifeSci Advisors LLC  
646-597-6987  
[Andrew@lifesciadvisors.com](mailto:Andrew@lifesciadvisors.com)